

Andrea Mazzanti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2494356/publications.pdf>

Version: 2024-02-01

91
papers

7,600
citations

147566

31
h-index

64668

79
g-index

97
all docs

97
docs citations

97
times ranked

8569
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>European Heart Journal</i> , 2015, 36, 2793-2867.	1.0	3,187
2	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, 17, euv319.	0.7	635
3	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 32.	18.1	347
4	Long-Term Follow-Up of Patients With Short QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2011, 58, 587-595.	1.2	301
5	Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. <i>International Journal of Cardiology</i> , 2020, 319, 106-114.	0.8	283
6	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. <i>European Heart Journal</i> , 2020, 41, 1414-1429.	1.0	239
7	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Circulation</i> , 2020, 141, 1872-1884.	1.6	229
8	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome. <i>Circulation</i> , 2016, 133, 622-630.	1.6	201
9	Novel Insight Into the Natural History of Short QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1300-1308.	1.2	191
10	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1053-1058.	1.2	191
11	Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2540-2550.	1.2	148
12	Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1663-1671.	1.2	137
13	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. <i>Circulation</i> , 2020, 142, 324-338.	1.6	83
14	Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. <i>International Journal of Cardiology</i> , 2015, 190, 393-402.	0.8	69
15	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (<i>RyR2</i>). <i>Circulation Research</i> , 2017, 121, 525-536.	2.0	64
16	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3010-3015.	1.2	64
17	The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 727-743.	1.3	58
18	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. <i>Genetics in Medicine</i> , 2021, 23, 47-58.	1.1	57

#	ARTICLE	IF	CITATIONS
19	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. <i>Nature Genetics</i> , 2022, 54, 232-239.	9.4	55
20	Phenotype and prognostic correlations of the converter region mutations affecting the β^2 myosin heavy chain. <i>Heart</i> , 2015, 101, 1047-1053.	1.2	54
21	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1756-1765.	1.2	53
22	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 176.	0.4	48
23	Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation. <i>Circulation Research</i> , 2019, 124, 539-552.	2.0	48
24	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of <i>CASQ2</i> -Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2020, 142, 932-947.	1.6	44
25	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1772-1784.	1.2	44
26	Usefulness of exercise test in the diagnosis of short QT syndrome. <i>Europace</i> , 2015, 17, 628-634.	0.7	39
27	An International Multicenter Evaluation of Type 5 Long QT Syndrome. <i>Circulation</i> , 2020, 141, 429-439.	1.6	39
28	Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Heart Lung and Circulation</i> , 2016, 25, 777-783.	0.2	38
29	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 499-519.	0.6	33
30	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. <i>European Heart Journal</i> , 2022, 43, 3041-3052.	1.0	32
31	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. <i>Human Mutation</i> , 2018, 39, 1835-1846.	1.1	31
32	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. <i>Circulation</i> , 2020, 142, 513-515.	1.6	31
33	Risk Stratification in the Long QT Syndrome. <i>Cardiac Electrophysiology Clinics</i> , 2012, 4, 53-60.	0.7	27
34	Big Data as a Driver for Clinical Decision Support Systems: A Learning Health Systems Perspective. <i>Frontiers in Digital Humanities</i> , 2018, 5, .	1.2	27
35	The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1226-1236.	0.8	26
36	Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2592-2612.	1.2	26

#	ARTICLE	IF	CITATIONS
37	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). <i>Europace</i> , 2022, 24, 614-619.	0.7	26
38	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β -Blockers. <i>JAMA Cardiology</i> , 2022, 7, 504.	3.0	26
39	From decision to shared-decision: Introducing patients's preferences into clinical decision analysis. <i>Artificial Intelligence in Medicine</i> , 2015, 65, 19-28.	3.8	25
40	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. <i>Heart Rhythm</i> , 2019, 16, 1468-1474.	0.3	22
41	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 937-943.	0.8	17
42	Arrhythmic Mitral Valve Prolapse: Introducing an Era of Multimodality Imaging-Based Diagnosis and Risk Stratification. <i>Diagnostics</i> , 2021, 11, 467.	1.3	16
43	Molecular Autopsy for Sudden Unexplained Death? Time to Discuss Pros and Cons. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1099-1102.	0.8	14
44	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, .	2.1	14
45	UceWeb: a Web-based Collaborative Tool for Collecting and Sharing Quality of Life Data. <i>Methods of Information in Medicine</i> , 2015, 54, 156-163.	0.7	13
46	Gquest: Modeling patient questionnaires and administering them through a mobile platform application. <i>Computer Methods and Programs in Biomedicine</i> , 2014, 117, 277-291.	2.6	12
47	The interpretation of genetic tests in inherited cardiovascular diseases. <i>Neurology International</i> , 2011, 1, 8.	0.2	11
48	Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1124-1132.	0.8	11
49	Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. <i>Current Opinion in Pediatrics</i> , 2017, 29, 552-559.	1.0	11
50	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome. <i>Frontiers in Physiology</i> , 2020, 11, 616819.	1.3	11
51	Graphical Representation of Life Paths to Better Convey Results of Decision Models to Patients. <i>Medical Decision Making</i> , 2015, 35, 398-402.	1.2	9
52	Genetic causes of sudden cardiac death in the young. <i>Current Opinion in Cardiology</i> , 2017, 32, 253-261.	0.8	9
53	Genetic risk stratification in cardiac arrhythmias. <i>Current Opinion in Cardiology</i> , 2018, 33, 298-303.	0.8	9
54	2015 ESC GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH VENTRICULAR ARRHYTHMIAS AND THE PREVENTION OF SUDDEN CARDIAC DEATH. <i>Russian Journal of Cardiology</i> , 2016, , 5-86.	0.4	9

#	ARTICLE	IF	CITATIONS
55	Genotype-Phenotype Correlation of <i>SCN5A</i> Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Proband. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003222.	1.6	7
56	Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 68, 624-625.	1.2	5
57	Outcomes of manual versus remote magnetic navigation for catheter ablation of ventricular tachycardia: a systematic review and updated meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1102-1114.	0.5	5
58	Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1868-1869.	1.2	4
59	Ranolazine as an Alternative Therapy to Flecainide for <i>SCN5A</i> V411M Long QT Syndrome Type 3 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 580481.	1.6	4
60	Sudden death in lambda light chain AL cardiac amyloidosis: a review of literature and update for clinicians and pathologists. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 1474-1482.	0.5	4
61	Safety and efficacy of catheter ablation for ventricular tachycardia in elderly patients with structural heart disease: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2023, 66, 179-192.	0.6	4
62	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment—Authors' reply. <i>Europace</i> , 2022, 24, 698-699.	0.7	4
63	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 248-249.	1.2	2
64	Outcomes and management of arrhythmogenic right ventricular cardiomyopathy in pregnancy: a case report. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-5.	0.3	2
65	Desmoplakin cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy: two distinct forms of cardiomyopathy?. <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	0.4	2
66	Identification of a <i>SCN5A</i> founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy. <i>Heart Rhythm</i> , 2021, 18, 1698-1706.	0.3	2
67	Conduction disorder and primary cardiac tumor: a fatal case of multiple lipomas of the right atrium. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 431-433.	0.2	2
68	Short QT Syndromes. <i>Cardiac Electrophysiology Clinics</i> , 2010, 2, 551-558.	0.7	1
69	Los estudios genéticos en la prevención de la muerte súbita: ¿realidad o ficción?. <i>CardiCore</i> , 2012, 47, 50-53.	0.0	1
70	Diagnosis of Long QT Syndrome: Time to Stand Up!. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 898-900.	0.4	1
71	Diagnóstico del síndrome de QT largo: valor del ortostatismo. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 898-900.	0.6	1
72	Warning: not all carriers of pathogenic mutations in desmosomal genes should follow the same medical advices!. <i>Cardiovascular Research</i> , 2020, 116, 1085-1088.	1.8	1

#	ARTICLE	IF	CITATIONS
73	Is mexiletine ready for prime time in patients with Type 2 Long QT Syndrome?. European Heart Journal, 2020, 41, .	1.0	1
74	Novel insights on Andersen-Tawil syndrome type 1. European Heart Journal, 2020, 41, .	1.0	1
75	"Ten Commandments" of 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 2015, 36, 2759.	1.0	1
76	Abstract 23071: Hydroquinidine Abolishes Life-threatening Arrhythmic Events in Patients With Short QT Syndrome. Circulation, 2017, 136, .	1.6	1
77	Genetic Arrhythmias (Channelopathies). , 0, , 198-209.		0
78	Early Repolarization is Associated with Short QT Syndrome in Italian Cohort. Annals of Global Health, 2018, 83, 183.	0.8	0
79	Molecular Basis of Mexiletine Response Variability in Sodium Channels with Long QT Mutations. Biophysical Journal, 2018, 114, 636a.	0.2	0
80	Catecholaminergic Polymorphic Ventricular Tachycardia. , 2022, , 167-183.		0
81	Inherited Arrhythmias: LQTS/SQTS/CPVT. , 2018, , 413-435.		0
82	Monogenic and oligogenic cardiovascular diseases: genetics of arrhythmias—long QT syndrome. , 2018, , 671-676.		0
83	Personalized therapies for cardiac channelopathies. , 2018, , 3005-3010.		0
84	Characterization of arrhythmic presentation in patients with arrhythmogenic cardiomyopathy. European Heart Journal, 2020, 41, .	1.0	0
85	Mutation site-specific risk profile in patients with Type 1 Long QT Syndrome. European Heart Journal, 2020, 41, .	1.0	0
86	Automated screening tool for Subcutaneous Implantable Defibrillator in Brugada syndrome has a high eligibility rate which is predicted by simple electrocardiographic parameters. European Heart Journal, 2020, 41, .	1.0	0
87	Role of CACNA1C variants in Brugada syndrome: clinical aspects and genetic testing strategies. European Heart Journal, 2020, 41, .	1.0	0
88	La estimulaci3n el3ctrica programada para la predicci3n del riesgo en pacientes con s3ndrome de Brugada: 2tiempo de cierre?. Revista Espanola De Cardiologia, 2022, , .	0.6	0
89	764—Prevalence and clinical implications of cardiac involvement in individuals with paucisymptomatic SARS-CoV-2 infection. European Heart Journal Supplements, 2021, 23, .	0.0	0
90	769—Differential pharmacological modulation of arrhythmic phenotype in catecholaminergic polymorphic ventricular tachycardia: not all betablockers are the same. European Heart Journal Supplements, 2021, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
91	Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time?. Revista Espanola De Cardiologia (English Ed), 2021, 75, 545-545.	0.4	0